Zion Pharma Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Zion Pharma Limited - overview
Established
2018
Location
Shanghai, -, China
Primary Industry
Pharmaceuticals
About
Based in Shanghai, China and established in 2018, Zion Pharma Limited is a bio-pharmaceutical company that focuses on the development of small molecule tumor drugs. Dr. Ziqiang Cheng, the company's co-founder and CEO, served as Director of Drug Metabolic Pharmacokinetics (DMPK) of AstraZeneca and GlaxoSmithKline The company engages in the development of small molecule tumor drugs. Its main product is ZN-A-1041.
ZN-A-1041 is a best-in-class small molecule tyrosine kinase receptor inhibitor targeting HER2. It is used in the treatment of HER2 and advanced breast cancer brain metastases. The company also created a new drug discovery platform.
Current Investors
MED-FINE Capital, TF Capital, Qiming Venture Partners
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.zionpharma.com
Verticals
HealthTech
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.